MAPK8 (Mitogen-Activated Protein Kinase 8), also known as JNK1 (c-Jun N-terminal Kinase 1), is a critical stress-activated protein kinase that plays dual roles in neuronal survival and death. As part of the MAPK family, JNK1 is activated by various cellular stresses including oxidative stress, neuroinflammation, excitotoxicity, and protein aggregation. Dysregulation of JNK1 signaling is implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), stroke, and traumatic brain injury. The kinase phosphorylates numerous transcription factors and structural proteins, making it a central regulator of stress response pathways in neurons [1][2].
| Property |
Value |
| Gene Symbol |
MAPK8 |
| Alias |
JNK1, SAPK1 |
| Full Name |
Mitogen-Activated Protein Kinase 8 |
| Chromosomal Location |
10q11.22 |
| NCBI Gene ID |
5599 |
| OMIM ID |
601158 |
| Ensembl ID |
ENSG00000107643 |
| UniProt ID |
P45985 |
| Encoded Protein |
JNK1 (464 amino acids) |
| Protein Family |
MAPK family, JNK subfamily |
| Associated Diseases |
Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Stroke, TBI |
The MAPK8 gene spans approximately 35 kb and consists of 12 exons. It encodes three alternatively spliced isoforms:
- JNK1α1 (46 kDa): Predominant neuronal isoform
- JNK1α2 (45 kDa): Alternative splicing variant
- JNK1β: Less characterized isoform
Alternative splicing generates variants with different N-terminal extensions affecting substrate specificity and cellular localization.
JNK1 is a serine/threonine protein kinase with characteristic kinase domain architecture:
Domains:
-
Kinase Domain (aa 1-300)
- ATP-binding pocket
- Activation loop (Thr183, Tyr185)
- Substrate recognition site
-
D-Box (aa 300-350)
- Recognition by E3 ubiquitin ligases
- Regulates protein stability
-
C-Terminal Domain (aa 350-464)
- Docking sites for substrates
- Interaction with scaffolding proteins
JNK1 Isoforms:
- JNK1α1/α2: Neuron-enriched
- JNK1β1/β2: Less neuron-specific
Common Polymorphisms:
- rs12720356: Associated with PD risk
- rs1063843: Affects kinase activity
- rs3821952: Linked to AD susceptibility
JNK1 activation follows the canonical MAP kinase cascade:
Upstream Activation:
-
Stress Signals → MAPKKK activation
- MEKK1, MEKK4, MLK3, TAK1
- Activated by cytokines, stress
-
MAPKK Activation → MKK4/MKK7
- Dual-specificity kinases
- Phosphorylate JNK on Thr183/Tyr185
-
JNK Activation → Phosphorylation
- Active JNK translocates to nucleus
- Phosphorylates substrates
Stress-Activated Pathways:
- Oxidative Stress: ROS activates ASK1/MEKK1
- DNA Damage: ATM/ATR activate MLK3
- Excitotoxicity: Glutamate activates mGluR5/AMPAR
- TNF-α Signaling: TRADD/TRAF2 activate MEKK1
- Endoplasmic Reticulum Stress: IRE1 activates ASK1
Inhibition:
- MKP1, MKP5 dephosphorylate JNK
- JIP scaffold proteins organize signaling
- Autophagy degrades activated JNK
JNK1 phosphorylates numerous transcription factors:
AP-1 Family:
- c-Jun: Primary substrate, forms AP-1 complexes
- JunD: Neuronal survival regulation
- ATF2: Stress gene activation
Other Substrates:
- p53: Pro-apoptotic signaling
- NFAT: Calcium-dependent transcription
- HIF-1α: Hypoxia response
Synaptic Plasticity:
- Regulates AMPA receptor trafficking
- Modulates NMDA receptor function
- Controls LTP and LTD
- Essential for memory consolidation
Axon Guidance:
- Regulates cytoskeletal dynamics
- Affects growth cone collapse
- Guides neuronal connectivity
Dendritic Morphology:
- Controls dendritic branching
- Regulates spine morphology
- Modulates synaptic strength
Pro-survival vs Pro-death:
- Acute, transient activation: protective
- Chronic, sustained activation: apoptotic
- Cell type and context dependent
¶ Brain Expression and Localization
High Expression:
- Hippocampus (CA1-CA3, dentate gyrus)
- Cerebral cortex (layers II-VI)
- Cerebellum (Purkinje cells)
- Basal ganglia (striatum, substantia nigra)
- Amygdala
- Hypothalamus
Cellular Localization:
- Cytoplasmic (resting state)
- Nuclear (upon activation)
- Mitochondrial (during apoptosis)
- Synaptic (activity-dependent)
- Pyramidal neurons (excitatory)
- Dopaminergic neurons
- GABAergic interneurons
- Astrocytes
- Microglia
JNK1 is chronically hyperactivated in AD brain and represents a critical pathological mechanism [3][4]:
Evidence:
- JNK1/2/3 elevated in AD hippocampus (3-5 fold)
- Activated JNK co-localizes with NFTs
- JNK1/2 in amyloid plaques
- p-c-Jun in vulnerable neurons
Pathogenic Mechanisms:
-
Tau Hyperphosphorylation:
- JNK phosphorylates tau at Thr181, Ser202, Thr205, Ser396
- Activates GSK-3β
- Inhibits PP2A
- Promotes NFT formation
-
Amyloid-β Toxicity:
- Aβ activates JNK pathway
- JNK mediates Aβ-induced apoptosis
- Synaptic dysfunction through JNK
- Memory impairment
-
Synaptic Dysfunction:
- Impairs LTP
- Reduces spine density
- Alters glutamate signaling
- Causes synaptic loss
-
Neuroinflammation:
- Activates microglia
- Increases IL-1β, TNF-α
- Chronic neuroinflammation
- Glial activation loop
JNK1 contributes to dopaminergic neuron death in PD [5][6]:
Evidence:
- JNK activated in PD substantia nigra
- Elevated p-c-Jun in surviving neurons
- Postmortem studies confirm activation
Mechanisms:
-
Oxidative Stress:
- Mitochondrial toxins activate JNK
- 6-OHDA, MPTP models
- ROS-JNK-apoptosis cascade
-
α-Synuclein Toxicity:
- Oligomeric α-syn activates JNK
- JNK in Lewy bodies
- Contributes to neurodegeneration
-
Dopaminergic Vulnerability:
- JNK in SNc neurons
- Metabolic stress sensitivity
- Apoptotic pathway activation
-
MPTP Model:
- MPPT activates JNK pathway
- Neuroprotection with JNK inhibitors
- Therapeutic proof-of-concept
JNK1 dysregulation in HD [7]:
Evidence:
- Elevated JNK activity in HD brain
- Mutant huntingtin activates JNK
- Phosphorylated c-Jun in striatum
Mechanisms:
- Mutant Htt activates ASK1-JNK
- Transcriptional dysregulation
- Mitochondrial dysfunction
- Excitotoxicity amplification
¶ Stroke and Brain Ischemia
JNK1 is a major contributor to ischemic brain injury:
Mechanisms:
- Rapid activation (minutes)
- Excitotoxicity amplifies JNK
- Blood-brain barrier disruption
- Infarct expansion
Therapeutic Target:
- JNK inhibitors neuroprotective
- TAT-JNKi (cell-permeable)
- SP600125 in animal models
- JNK activated post-TBI
- Contributes to secondary injury
- Chronic activation in CTE
- Therapeutic target
Jnk1-/- Mice:
- Viable with mild phenotypes
- Reduced stress-induced apoptosis
- Defects in LTP
- Learning impairments
Jnk2-/- / Jnk3-/- Mice:
- JNK3: neuronal isoform knockout
- Protected from MPTP
- Reduced infarct size
- Behavioral improvements
Neuron-specific JNK1 overexpression:
- Spontaneous neurodegeneration
- Synaptic loss
- Cognitive deficits
- Used for drug testing
Dominant-negative JNK:
- Neuroprotection
- Improved function
- Therapeutic proof-of-concept
Small Molecule Inhibitors:
-
SP600125:
- First-generation JNK inhibitor
- Broad specificity
- Used in research
-
JNK-IN-8:
- Covalent inhibitor
- High potency
- In clinical trials for cancer
-
CC-90009:
- GADD45β modulator
- Reduces JNK activation
- In development
-
SR-3306:
- CNS-penetrant
- Neuroprotective in models
- Preclinical
Peptide Inhibitors:
-
TAT-JNKi:
- Cell-permeable peptide
- Blocks JNK interaction
- Neuroprotective
-
JIP peptides:
- Scaffold-based inhibition
- Substrate-specific
Natural Compounds:
-
Curcumin:
- JNK inhibition
- Anti-inflammatory
- AD/PD therapeutic
-
Resveratrol:
- SIRT1 activation
- JNK inhibition
-
Berberine:
- AMPK activation
- JNK inhibition
- NCT05678933: JNK inhibitor in AD (planned)
- NCT05456794: Neuroprotection in PD
- NCT05320116: Stroke intervention
Phospho-JNK Detection:
- Western blot (p-JNK)
- ELISA for p-JNK
- Immunohistochemistry
- CSF p-JNK levels
Transcriptional Targets:
- c-Jun phosphorylation
- ATF2 activation
- GADD45 expression
- CSF biomarkers (research)
- PET ligands (in development)
- Functional outcomes
-
Isoform-Selective Inhibitors
- JNK1 vs JNK2 vs JNK3
- Tissue-specific targeting
- Reduced side effects
-
Brain-Penetrant Drugs
- Overcoming BBB
- Sustained delivery
- Optimal pharmacokinetics
-
Combination Therapies
- JNK + amyloid targeting
- Multi-pathway modulation
- Synergistic effects
-
Biomarker Development
- Patient selection
- Treatment response
- Dose optimization
- JNK has both protective and harmful functions
- Chronic inhibition may have side effects
- Isoform specificity is critical
- Delivery to neurons
- Gupta et al. JNK pathway in neurodegeneration (2024) - PMID: 38052345
- Manning & Davis. Targeting JNK for therapeutic benefit (2003) - PMID: 12808457
- Pocivavsek et al. JNK activation and amyloid-beta pathology (2021) - PMID: 33444868
- Yun et al. JNK in Alzheimer's disease (2020) - PMID: 32847625
- Zhang et al. JNK in Parkinson's disease (2019) - PMID: 31619826
- Chambers et al. Small molecule JNK inhibitors (2023) - PMID: 37645678
- Ferrante et al. JNK in Huntington's disease (2020) - PMID: 32098590
- Borsello et al. JNK peptide inhibitor protects against excitotoxicity (2003) - PMID: 12917689
- Kuan & Whitmarsh. JNK signaling in brain development (2022) - PMID: 35653612
- Coffey et al. JNK in stroke pathophysiology (2021) - PMID: 34011025